FasTCAR-T GC012F demonstrated overall 100% response rate in newly diagnosed multiple myeloma
Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal outcomes. A high-efficacy, safe CAR-T treatment could address this large..
The Life-Changing Treatment for Blood Cancer Finally Exposed!
Blood cancer is a type of cancer that affects both the blood and bone marrow. It is the fifth most common type of cancer in the world, with around 1.24 million new cases diagnosed each year. Wondering is blood cancer curable? Fin..
NMPA Approves FUCASO: Multiple Myeloma Treatment In China
The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA's approval marks a turning point in China's fight against multiple myeloma. This blog explores the effectiveness of this therapy, its s..
Free Cancer Treatment In China Without Breaking The Bank: A Guide For Those Who Need It Most
Free cancer treatment in China is providing hope and healing to people in need. So, if you are unable to opt for cancer treatment because of its extensive cost, this guide is specially meant for you. Find out how reputed organiz..
An Informative Guide On The Whispering Signs And Symptoms Of Multiple Myeloma
Read our guide to learn about the silent indicators of multiple myeloma. Learn to spot them early, so you can make smart choices for your health. Don't ignore the warning signs, empower yourself with knowledge and take charge..
A Closer Look At The Various Stages Of Multiple Myeloma
Learn about the different stages and types of multiple myeloma. Find hope and support with information on treatments and coping strategies. This simple guide can help you take charge of your health and fight against multiple myel..
China, India
How Does Diagnostic Imaging Save Lives in Multiple Myeloma Battles?
Curious about how a medical technique is saving the lives of multiple myeloma patients? Read our blog to learn more about this life-saving technique! Let's turn the page on cancer together. Your story of hope starts here. Hell..
BCMA, Elranatamab-bcmm, multiple myeloma
Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma
Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administration for adults with relapsed or ..
Janssen Biotech, MonumenTAL-1, multiple myeloma, Talquetamab-tgvs, Talvey
Talquetamab-tgvs has received accelerated approval for relapsed or refractory multiple myeloma
August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma who have undergone at ..
CAR T Cell therapy trials, multiple myeloma trials
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
Brief Summary: A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma Detailed Description: This is a single arm, open-label, single-center stu..